Jamieson Wellness Inc. Reports Third Quarter 2022 Financial Results

 

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reported financial results for its third quarter ended September 30, 2022. All amounts are expressed in Canadian dollars. Certain metrics, including those expressed on an adjusted basis, are non-IFRS and other financial measures. See "Non-IFRS and Other Financial Measures" below.

 

  Highlights of Third Quarter 2022 versus Third Quarter 2021  

 
  • Total revenue increased to $138.9 million and Jamieson Brands revenue grew by 31.8%, including organic branded growth of 11.2%
  •  
  • Increased Adjusted EBITDA (1) by 15.9% to $29.5 million
  •  
  • Net earnings were $10.9 million and Adjusted net earnings (1) increased 1.2% to $14.2 million; and
  •  
  • Diluted earnings per share were $0.26, and Adjusted diluted earnings per share (2) remain flat at $0.34
  •  

"Our third quarter results reflect the ongoing strength of our branded business with continued strong consumer consumption," said Mike Pilato, President and CEO of Jamieson Wellness. "Total revenue increased nearly 24% including organic growth of almost 12% in our domestic branded business and nearly 30% growth in China. It's an exciting time at Jamieson Wellness, as we continue to accelerate our leadership beyond our 100-year anniversary with advancements in the United States and China, two of our key growth pillars. The initial stages of our youtheory integration are progressing well and we are confident in the strategic value of our expansion in the United States, as well as the potential for long-term revenue growth and profitability as we start to realize synergies. As announced separately today, we will acquire specific assets from our distribution partner in China enabling us to directly manage our brands, marketing and distribution in the country. This will bring us closer to our consumers in the world's second largest vitamin market and unlock opportunities to further position the Jamieson brand for growth. Our team continues to execute exceptionally well in a challenging macro environment, and we are on track for a strong finish to our 100 th year."

 

  Third Quarter 2022 Results  

 

Revenue increased 23.6% to $138.9 million in the third quarter of 2022 compared with $112.4 million in the third quarter of 2021 driven by 31.8% growth in the Jamieson Brands segment, partially offset by a 1.9% decline in the Strategic Partners segment.

 

Revenue in the Jamieson Brands segment increased by $27.1 million, or 31.8%, to $112.2 million in the third quarter of 2022. The acquisition of youtheory this quarter added the United States, the largest VMS market in the world, as a key strategic growth pillar in our plan. This transaction contributed $17.5 million or 20.6% incremental revenue this quarter. The Company's domestic branded sales increased by 11.7% in the third quarter of 2022, reflecting the timing of fourth quarter promotional shipments and continued consumer demand supporting our elevated consumer base. The Company's international revenue grew by 8.5% on a reported basis compared with the third quarter of 2021 driven by growth in China of 29.2% reflecting recovery after COVID-19 related lockdowns last quarter, along with the strengthening of the US dollar, offset by a 7.8% decline in rest of the world as a result of continued geopolitical pressures in eastern Europe impacting the macro-economic environment.

 

Revenue in the Strategic Partners segment decreased by $0.5 million, or 1.9%, to $26.7 million in the third quarter of 2022 reflecting order timing and strategic exit of certain low margin programs.

 

Gross profit increased by $7.7 million to $48.5 million in the third quarter of 2022 mainly driven by higher revenue, including the impact of the youtheory acquisition. Normalized gross profit margin (2) for the Company and normalized gross profit margin in Jamieson Brands segment each decreased by 140 basis points to 34.9% and by 400 basis points to 40.3%, respectively, reflecting the lower gross profit margin profile, higher depreciation expense and product mix of youtheory and its proportional mix in overall sales. Gross profit margin (3) in Strategic Partners increased by 80 basis points to 12.3% mainly due to favourable customer mix and pricing offsetting higher global supply chain and input costs.

 

Selling, general and administrative ("SG&A") expenses increased by $11.6 million to $30.9 million in the third quarter of 2022. Excluding the impact of specified costs of $7.2 million mainly comprised of acquisition related costs and IT system development and implementation costs, and the acquisition impact of youtheory of $4.2 million, SG&A expenses increased by $0.5 million or 2.8% to $17.9 million in the third quarter of 2022. Jamieson Brands incurred higher costs to support its strategic initiatives, which were partially offset by the timing of marketing investments which were weighted heavier in the first half of the year to support the launch of our 100-year anniversary campaign.

 

Earnings from operations decreased by $4.3 million, or 20.8%, to $16.3 million in the third quarter of 2022 and operating margin (3) decreased by 660 basis points to 11.7% due to factors affecting gross profit margin discussed above and higher SG&A expenses including specified cost mainly related to youtheory acquisition and IT system implementation. Normalized earnings from operations (1) increased by $2.7 million, or 12.9% in the third quarter of 2022 and normalized operating margin (2) was 16.9% compared with 18.5% in the third quarter of 2021.

 

Adjusted EBITDA increased by 15.9% to $29.5 million in the third quarter of 2022 and Adjusted EBITDA margin (2) was 21.2% compared with 22.7% in the third quarter of 2021. While gross profit margins are lower on the acquired youtheory business, Adjusted EBITDA margin (2) of Jamieson Brands remains strong at 24.2% in the quarter.

 

Interest expense and other financing costs increased by $2.6 million to $4.1 million due to higher average borrowing rates and higher borrowings to support the youtheory transaction in the quarter.

 

Net earnings for the third quarter of 2022 was $10.9 million compared with $14.3 million in the third quarter of 2021. Adjusted net earnings, which excludes all non-operating expenses and foreign exchange, increased by $0.2 million, or 1.2%, to $14.2 million in the third quarter of 2022.

 

Adjusted net earnings excludes costs associated with foreign exchange gain/loss, acquisition related costs, IT system improvements, COVID-19 related costs, business integration, and other non-operating earnings or expenses net of related tax effects. A quantitative reconciliation of reported net earnings to EBITDA, Adjusted EBITDA, and non-IFRS normalized gross profit, normalized SG&A, normalized earnings from operations and Adjusted net earnings are included in the table accompanying this release under the heading "Non-IFRS and Other Financial Measures".

 

  Balance Sheet & Cash Flow  

 

The Company used $20.6 million in cash from operations during the third quarter of 2022 compared with $10.1 million generated in the third quarter of 2021. Cash from operating activities before working capital considerations (1) of $16.4 million was $2.7 million lower due to decreased earnings in the current quarter as a result of expenses associated with the acquisition of youtheory. Cash investments in working capital increased by $28.0 million driven by the investment in youtheory working capital as anticipated, higher inventories to maintain continuity of supply and the timing of sales and collections within the quarter. The Company's cash as at September 30, 2022 was $7.3 million compared with $6.8 million on December 31, 2021 and $9.2 million at the end of the third quarter of 2021. The Company ended the quarter with approximately $95.9 million in cash and available operating lines and net debt (1) of $404.1 million.

 
                                                                                                                                                                            
   Three months ended      
   September 30      
  ($ in 000's, except as otherwise noted)   

  2022  

 
  

  2021  

 
   $ Change     % Change  
        
Cash, beginning of period  

  8,357  

 
  

  4,636  

 
  

  3,721  

 
  

  80.3%  

 
Cash flows from (used in):        
Operating activities  

(20,613)

 
  

10,081

 
  

(30,694)

 
  

(304.5%)

 
Investing activities  

(245,609)

 
  

(6,615)

 
  

(238,994)

 
  

(3612.9%)

 
Financing activities  

265,181

 
  

1,048

 
  

264,133

 
  

25203.5%

 
  Cash, end of period   

  7,316  

 
  

  9,150  

 
  

  (1,834)  

 
  

  (20.0%)  

 
        
Cash flows from operating activities  

(20,613)

 
  

10,081

 
  

(30,694)

 
  

(304.5%)

 
Net Change in non-cash working capital  

37,042

 
  

9,078

 
  

27,964

 
  

308.0%

 
  Cash from operating activities before working capital considerations   

  16,429  

 
  

  19,159  

 
  

  (2,730)  

 
  

  (14.2%)  

 
        
        
  ($ in 000's, except as otherwise noted)        As at September 30, 2022     As at December 31, 2021  
        
  Long-term debt       

  411,385  

 
  

  149,125  

 
Cash      

(7,316)

 
  

(6,775)

 
  Net debt       

  404,069  

 
  

  142,350  

 
        
 

  Fiscal 2022 Outlook  

 

The Company is narrowing its outlook for fiscal 2022 and anticipates revenue in the range of $550.0 to $560.0 million, which represents annual growth of 6.0% to 8.0% in the base business plus revenue growth of approximately 16.0% from the acquisition. The Company estimates Adjusted EBITDA in the range of $122.0 to $124.0 million and Adjusted diluted earnings per share in the range of $1.52 to $1.56.

 

For additional details on the Company's fiscal 2022 outlook, including guidance for the fourth quarter of 2022, refer to the "Outlook" section in the management's discussion and analysis of financial condition and results of operations ("MD&A") for the three and nine months ended September 30, 2022.

 

  Declaration of Third Quarter Dividend  

 

The board of directors of the Company authorized and declared a cash dividend for the third quarter of 2022 of $0.17 per common share, or approximately $7.2 million in the aggregate. The dividend will be paid on December 15, 2022 to all common shareholders of record at the close of business on December 1, 2022. The Company has designated this dividend as an "eligible dividend" for the purposes of the Income Tax Act (Canada).

 

  ___________
  (1) This is a non-IFRS financial measure. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each non-IFRS financial measure.
(2) This is a non-IFRS ratio. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each non-IFRS ratio.
(3) This is a supplementary financial measure. See the " Non-IFRS and Other Financial Measures " section of this press release for more information on each supplementary financial measure.

 

  Consolidated Financial Statements and Management's Discussion and Analysis  

 

The Company's unaudited condensed consolidated interim financial statements and accompanying notes as at and for the three and nine months ended September 30, 2022 and related MD&A are available under the Company's profile on SEDAR at   www.sedar.com   and on the Investor Relations section of the Company's website at https://investors.jamiesonwellness.com .

 

  Conference Call  

 

Management will host a conference call to discuss the Company's third quarter 2022 results at 5:00 p.m. ET today, November 3, 2022. The call can be accessed live over the telephone by dialing 1-888-204-4368 from Canada and the U.S. or 1-323-994-2093 from international locations. A replay will be available shortly after the call and can be accessed by dialing 1-844-512-2921 from Canada and the U.S. or 1-412-317-6671 from international locations. The passcode for the replay is 7518646 and it will be available until Thursday November 17, 2022.

 

Interested parties may listen to a simultaneous webcast of the conference call by logging on via the Investor Relations section of the Company's website at https://investors.jamiesonwellness.com or directly at https://viavid.webcasts.com/starthere.jsp?ei=1568803&tp_key=3467792580 . A replay of the webcast will be available for approximately 30 days following the call.

 

  About Jamieson Wellness  

 

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness also offers a variety of VMS products under its youtheory, Progressive, Smart Solutions, Iron Vegan and Precision brands. The Company is a participant of the United Nations Global Compact and adheres to its principles-based approach to responsible business. For more information please visit www.jamiesonwellness.com .

 

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

 

  Forward-Looking Information  

 

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's anticipated results and its outlook for its 2022 revenue, Adjusted EBITDA and Adjusted diluted earnings per share. Words such as "expect", "anticipate", "intend", "may", "will", "estimate" and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 29, 2022 and under the "Risk Factors" section in the MD&A filed today, November 3, 2022. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

 

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

 

  Jamieson Wellness Inc.
Selected Consolidated Financial Information
In thousands of Canadian dollars, except share and per share amounts

 
                                                                                                                                                                                                                                                                                
   Three months ended     Nine months ended  
   September 30     September 30  
  

  2022  

 
  

  2021  

 
  

  2022  

 
  

  2021  

 
        
  Revenue   

  138,929  

 
  

  112,368  

 
  

  354,594  

 
  

  321,194  

 
Cost of sales  

90,440

 
  

71,555

 
  

227,445

 
  

208,169

 
Gross profit  

48,489

 
  

40,813

 
  

127,149

 
  

113,025

 
        
  Gross profit margin   

  34.9%  

 
  

  36.3%  

 
  

  35.9%  

 
  

  35.2%  

 
        
Selling, general and administrative expenses  

30,855

 
  

19,228

 
  

77,471

 
  

61,218

 
Share-based compensation  

1,315

 
  

992

 
  

3,593

 
  

4,651

 
  Earnings from operations   

  16,319  

 
  

  20,593  

 
  

  46,085  

 
  

  47,156  

 
        
  Operating margin   

  11.7%  

 
  

  18.3%  

 
  

  13.0%  

 
  

  14.7%  

 
        
Foreign exchange gain  

(759)

 
  

(577)

 
  

(709)

 
  

(444)

 
Interest expense and other financing costs  

4,144

 
  

1,505

 
  

6,660

 
  

4,291

 
Earnings before income taxes  

12,934

 
  

19,665

 
  

40,134

 
  

43,309

 
Provision for income taxes  

2,052

 
  

5,381

 
  

9,417

 
  

11,417

 
  Net earnings   

  10,882  

 
  

  14,284  

 
  

  30,717  

 
  

  31,892  

 
  Adjusted net earnings   

  14,221  

 
  

  14,051  

 
  

  38,381  

 
  

  34,728  

 
        
  EBITDA   

  21,744  

 
  

  24,794  

 
  

  58,967  

 
  

  58,171  

 
  Adjusted EBITDA   

  29,505  

 
  

  25,456  

 
  

  74,890  

 
  

  66,325  

 
  Adjusted EBITDA margin   

  21.2%  

 
  

  22.7%  

 
  

  21.1%  

 
  

  20.6%  

 
        
  Weighted average number of shares         
Basic  

41,386,719

 
  

40,256,983

 
  

40,766,991

 
  

40,076,485

 
Diluted  

42,449,242

 
  

41,698,267

 
  

41,813,337

 
  

41,500,445

 
        
  Earnings per share attributable to common shareholders:         
Basic, earnings per share  

  0.26  

 
  

  0.35  

 
  

  0.75  

 
  

  0.80  

 
Diluted, earnings per share  

  0.26  

 
  

  0.34  

 
  

  0.73  

 
  

  0.77  

 
Adjusted diluted, earnings per share  

  0.34  

 
  

  0.34  

 
  

  0.92  

 
  

  0.84  

 
 

  Jamieson Wellness Inc.
Consolidated Statements of Financial Position
In thousands of Canadian dollars

 
                                                                                                                                                    
   September 30,
2022
 
   December 31,
2021
 
  Assets     
  Current assets     
Cash  

7,316

 
  

6,775

 
Accounts receivable  

143,389

 
  

104,186

 
Inventories  

169,685

 
  

119,006

 
Derivatives  

7,805

 
  

2,149

 
Prepaid expenses and other current assets  

4,376

 
  

5,029

 
  

  332,571  

 
  

  237,145  

 
  Non-current assets     
Property, plant and equipment  

113,538

 
  

96,977

 
Goodwill  

275,064

 
  

122,975

 
Intangible assets  

370,808

 
  

192,676

 
Deferred income tax  

4,082

 
  

2,702

 
  Total assets   

  1,096,063  

 
  

  652,475  

 
    
  Liabilities     
  Current liabilities     
Accounts payable and accrued liabilities  

132,352

 
  

74,533

 
Income taxes payable  

804

 
  

2,896

 
Derivatives  

1,728

 
  

3,317

 
Current portion of long-term debt  

11,147

 
  

2,876

 
  

  146,031  

 
  

  83,622  

 
  Long-term liabilities     
Long-term debt  

411,385

 
  

149,125

 
Post-retirement benefits  

3,798

 
  

3,544

 
Deferred income tax  

58,182

 
  

53,291

 
Other long-term liabilities  

60,641

 
  

20,872

 
  Total liabilities   

  680,037  

 
  

  310,454  

 
    
  Shareholders' equity     
Share capital  

306,704

 
  

268,214

 
Contributed surplus  

15,843

 
  

14,786

 
Retained earnings  

70,496

 
  

58,998

 
Accumulated other comprehensive income  

22,983

 
  

23

 
  Total shareholders' equity   

  416,026  

 
  

  342,021  

 
  Total liabilities and shareholders' equity   

  1,096,063  

 
  

  652,475  

 
 

  Jamieson Wellness Inc.
Segment Information
In thousands of Canadian dollars, except as otherwise noted

 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Jamieson Brands         
         
    Three months ended
September 30
 
    
   

  2022  

 
  

  2021  

 
   $ Change     % Change  
         
  Revenue  

112,248

 
  

85,175

 
  

27,073

 
  

31.8%

 
         
  Gross profit  

45,202

 
  

37,690

 
  

7,512

 
  

19.9%

 
  Gross profit margin  

40.3%

 
  

44.3%

 
  

-

 
  

(4.0%)

 
         
  Normalized gross profit  

45,202

 
  

37,717

 
  

7,485

 
  

19.8%

 
  Normalized gross profit margin  

40.3%

 
  

44.3%

 
  

-

 
  

(4.0%)

 
         
  Selling, general and administrative expenses  

29,332

 
  

17,645

 
  

11,687

 
  

66.2%

 
  Normalized selling, general and administrative expenses  

22,127

 
  

17,437

 
  

4,690

 
  

26.9%

 
         
  Share-based compensation  

1,315

 
  

992

 
  

323

 
  

32.6%

 
         
   Earnings from operations   

  14,555  

 
  

  19,053  

 
  

  (4,498)  

 
  

  (23.6%)  

 
   Operating margin   

  13.0%  

 
  

  22.4%  

 
  

  -  

 
  

  (9.4%)  

 
         
   Normalized earnings from operations   

  21,760  

 
  

  19,288  

 
  

  2,472  

 
  

  12.8%  

 
   Normalized operating margin   

  19.4%  

 
  

  22.6%  

 
  

  -  

 
  

  (3.2%)  

 
         
   Adjusted EBITDA   

  27,158  

 
  

  23,363  

 
  

  3,795  

 
  

  16.2%  

 
   Adjusted EBITDA margin   

  24.2%  

 
  

  27.4%  

 
  

  -  

 
  

  (3.2%)  

 
         
         
  Strategic Partners         
         
    Three months ended
September 30
 
    
   

  2022  

 
  

  2021  

 
   $ Change     % Change  
         
  Revenue  

26,681

 
  

27,193

 
  

(512)

 
  

(1.9%)

 
         
  Gross profit  

3,287

 
  

3,123

 
  

164

 
  

5.3%

 
  Gross profit margin  

12.3%

 
  

11.5%

 
  

-

 
  

0.8%

 
         
  Selling, general and administrative expenses  

1,523

 
  

1,583

 
  

(60)

 
  

(3.8%)

 
  Normalized selling, general and administrative expenses  

1,523

 
  

1,570

 
  

(47)

 
  

(3.0%)

 
         
   Earnings from operations   

  1,764  

 
  

  1,540  

 
  

  224  

 
  

  14.5%  

 
   Operating margin   

  6.6%  

 
  

  5.7%  

 
  

  -  

 
  

  0.9%  

 
         
   Normalized earnings from operations   

  1,764  

 
  

  1,553  

 
  

  211  

 
  

  13.6%  

 
   Normalized operating margin   

  6.6%  

 
  

  5.7%  

 
  

  -  

 
  

  0.9%  

 
         
   Adjusted EBITDA   

  2,347  

 
  

  2,093  

 
  

  254  

 
  

  12.1%  

 
   Adjusted EBITDA margin   

  8.8%  

 
  

  7.7%  

 
  

  -  

 
  

  1.1%  

 
         
         
  Jamieson Brands         
         
    Six months ended
September 30
 
    
   

  2022  

 
  

  2021  

 
   $ Change     % Change  
         
  Revenue  

283,151

 
  

243,461

 
  

39,690

 
  

16.3%

 
         
  Gross profit  

118,694

 
  

103,214

 
  

15,480

 
  

15.0%

 
  Gross profit margin  

41.9%

 
  

42.4%

 
  

-

 
  

(0.5%)

 
         
  Normalized gross profit  

118,694

 
  

103,867

 
  

14,827

 
  

14.3%

 
  Normalized gross profit margin  

41.9%

 
  

42.7%

 
  

-

 
  

(0.8%)

 
         
  Selling, general and administrative expenses  

72,831

 
  

56,151

 
  

16,680

 
  

29.7%

 
  Normalized selling, general and administrative expenses  

59,840

 
  

53,074

 
  

6,766

 
  

12.7%

 
         
  Share-based compensation  

3,593

 
  

4,651

 
  

(1,058)

 
  

(22.7%)

 
         
   Earnings from operations   

  42,270  

 
  

  42,412  

 
  

  (142)  

 
  

  (0.3%)  

 
   Operating margin   

  14.9%  

 
  

  17.4%  

 
  

  -  

 
  

  (2.5%)  

 
         
   Normalized earnings from operations   

  55,261  

 
  

  46,142  

 
  

  9,119  

 
  

  19.8%  

 
   Normalized operating margin   

  19.5%  

 
  

  19.0%  

 
  

  -  

 
  

  0.5%  

 
         
   Adjusted EBITDA   

  69,256  

 
  

  59,833  

 
  

  9,423  

 
  

  15.7%  

 
   Adjusted EBITDA margin   

  24.5%  

 
  

  24.6%  

 
  

  -  

 
  

  (0.1%)  

 
         
         
  Strategic Partners         
         
    Six months ended
September 30
 
    
   

  2022  

 
  

  2021  

 
   $ Change     % Change  
         
  Revenue  

71,443

 
  

77,733

 
  

(6,290)

 
  

(8.1%)

 
         
  Gross profit  

8,455

 
  

9,811

 
  

(1,356)

 
  

(13.8%)

 
  Gross profit margin  

11.8%

 
  

12.6%

 
  

-

 
  

(0.8%)

 
         
  Selling, general and administrative expenses  

4,640

 
  

5,067

 
  

(427)

 
  

(8.4%)

 
  Normalized selling, general and administrative expenses  

4,592

 
  

4,850

 
  

(258)

 
  

(5.3%)

 
         
   Earnings from operations   

  3,815  

 
  

  4,744  

 
  

  (929)  

 
  

  (19.6%)  

 
   Operating margin   

  5.3%  

 
  

  6.1%  

 
  

  -  

 
  

  (0.8%)  

 
         
   Normalized earnings from operations   

  3,863  

 
  

  4,961  

 
  

  (1,098)  

 
  

  (22.1%)  

 
   Normalized operating margin   

  5.4%  

 
  

  6.4%  

 
  

  -  

 
  

  (1.0%)  

 
         
   Adjusted EBITDA   

  5,634  

 
  

  6,492  

 
  

  (858)  

 
  

  (13.2%)  

 
   Adjusted EBITDA margin   

  7.9%  

 
  

  8.4%  

 
  

  -  

 
  

  (0.5%)  

 
 

  Non-IFRS and Other Financial Measures  

 

This press release makes reference to certain financial measures, including non-IFRS financial measures that are historical, non-IFRS measures that are forward-looking, non-GAAP ratios and supplementary financial measures. Management uses these financial measures for purposes of comparison to prior periods and development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of ongoing operations and in analyzing the Company's business performance and trends. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of the Company's financial information reported under IFRS. The Company uses the following non‑IFRS financial measures: "EBITDA", "Adjusted EBITDA" and "Adjusted net earnings", the most directly comparable financial measure for each that is disclosed in its financial statements being net earnings, "normalized gross profit", "normalized SG&A", "normalized earnings from operations", "cash from operating activities before working capital considerations" and "net debt", the most directly comparable financial measures for each that is disclosed in its financial statements being gross profit, SG&A, earnings from operations, cash flows from operating activities, and long-term debt, respectively, the following non-IFRS ratios: "Adjusted EBITDA margin", "Adjusted diluted earnings per share", "normalized gross profit margin", "normalized operating margin", and the following supplementary financial measures: "gross profit margin" and "operating margin" to provide supplemental measures of the Company's operating performance and thus highlight trends in the Company's core business that may not otherwise be apparent when relying solely on IFRS financial measures. Management also uses non‑IFRS and supplementary financial measures in order to prepare annual operating budgets and to determine components of management compensation. For an explanation of the composition of each such measure and the usefulness and additional uses of each by management, see the " How we Assess the Performance of our Business " section of the MD&A, which is incorporated by reference. See below for a quantitative reconciliation of each non-IFRS financial measure to its most directly comparable financial measure disclosed in the Company's financial statements to which the measure relates.

 

The following tables provide a quantitative reconciliation of net earnings to EBITDA, Adjusted EBITDA, and Adjusted net earnings, as well as gross profit to normalized gross profit, SG&A to normalized SG&A, earnings from operations to normalized earnings from operations, each of which are non-IFRS financial measures (see the " Non-IFRS and Other Financial Measures " of this press release for further information on each non-IFRS financial measure) for the three and nine months ended September 30, 2022 and September 30, 2021.

 

  Reconciliation of Non-IFRS Financial Measures
In thousands of Canadian dollars

 
                                                                                                                                                                                                                                                                                                                                                                                                                                                
   Three months ended     Nine months ended  
   September 30     September 30  
  

  2022  

 
  

  2021  

 
  

  2022  

 
  

  2021  

 
        
  Net earnings   

  10,882  

 
  

  14,284  

 
  

  30,717  

 
  

  31,892  

 
  Add:         
Provision for income taxes  

2,052

 
  

5,381

 
  

9,417

 
  

11,417

 
Interest expense and other financing costs  

4,144

 
  

1,505

 
  

6,660

 
  

4,291

 
Depreciation of property, plant, and equipment  

3,194

 
  

2,543

 
  

8,574

 
  

7,377

 
Amortization of intangible assets  

1,472

 
  

1,081

 
  

3,599

 
  

3,194

 
        
  Earnings before interest, taxes, depreciation, and amortization (EBITDA)   

  21,744  

 
  

  24,794  

 
  

  58,967  

 
  

  58,171  

 
  Add EBITDA adjustments:         
Share-based compensation (1)  

1,315

 
  

992

 
  

3,593

 
  

4,651

 
Foreign exchange gain  

(759)

 
  

(577)

 
  

(709)

 
  

(444)

 
Acquisition related cost (2)  

6,270

 
  

-

 
  

9,754

 
  

-

 
IT system implementation (3)  

934

 
  

-

 
  

3,110

 
  

-

 
COVID-19 related costs (4)  

1

 
  

159

 
  

175

 
  

2,337

 
Business integration (5)  

-

 
  

88

 
  

-

 
  

1,789

 
Other  

-

 
  

-

 
 

 

 
 

-

 
  

(179)

 
  Adjusted EBITDA   

  29,505  

 
  

  25,456  

 
  

  74,890  

 
  

  66,325  

 
Provision for income taxes  

(2,052)

 
  

(5,381)

 
  

(9,417)

 
  

(11,417)

 
Interest expense and other financing costs  

(4,144)

 
  

(1,505)

 
  

(6,660)

 
  

(4,291)

 
Depreciation of property, plant, and equipment  

(3,194)

 
  

(2,543)

 
  

(8,574)

 
  

(7,377)

 
Amortization of intangible assets  

(1,472)

 
  

(1,081)

 
  

(3,599)

 
  

(3,194)

 
Share-based compensation (6)  

(2,714)

 
  

(982)

 
  

(4,992)

 
  

(4,389)

 
Tax effect of normalization adjustments  

(1,708)

 
  

87

 
  

(3,267)

 
  

(929)

 
  Adjusted net earnings   

  14,221  

 
  

  14,051  

 
  

  38,381  

 
  

  34,728  

 
        
        
   Three months ended     Nine months ended  
   September 30     September 30  
  

  2022  

 
  

  2021  

 
  

  2022  

 
  

  2021  

 
        
  Gross profit   

48,489

 
  

40,813

 
  

  127,149  

 
  

  113,025  

 
Business integration (5)  

-

 
  

27

 
  

-

 
  

653

 
  Normalized gross profit   

  48,489  

 
  

  40,840  

 
  

  127,149  

 
  

  113,678  

 
  Normalized gross profit margin   

  34.9%  

 
  

  36.3%  

 
  

  35.9%  

 
  

  35.4%  

 
        
  Selling, general and administrative expenses   

30,855

 
  

19,228

 
  

  77,471  

 
  

  61,218  

 
Acquisition related cost (2)  

(6,270)

 
  

-

 
  

(9,754)

 
  

-

 
IT system implementation (3)  

(934)

 
  

-

 
  

(3,110)

 
  

-

 
COVID-19 related costs (4)  

(1)

 
  

(159)

 
  

(175)

 
  

(2,337)

 
Business integration (5)  

-

 
  

(62)

 
  

-

 
  

(1,136)

 
Other  

-

 
  

-

 
  

-

 
  

179

 
  Normalized selling, general and administrative expenses   

  23,650  

 
  

  19,007  

 
  

  64,432  

 
  

  57,924  

 
        
  Earnings from operations   

  16,319  

 
  

  20,593  

 
  

  46,085  

 
  

  47,156  

 
Acquisition related cost (2)  

6,270

 
  

-

 
  

9,754

 
  

-

 
IT system implementation (3)  

934

 
  

-

 
  

3,110

 
  

-

 
COVID-19 related costs (4)  

1

 
  

159

 
  

175

 
  

2,337

 
Business integration (5)  

-

 
  

89

 
  

-

 
  

1,789

 
Other  

-

 
  

-

 
  

-

 
  

(179)

 
  Normalized earnings from operations   

  23,524  

 
  

  20,841  

 
  

  59,124  

 
  

  51,103  

 
  Normalized operating margin   

  16.9%  

 
  

  18.5%  

 
  

  16.7%  

 
  

  15.9%  

 
        
 
                  
 

(1)

 
  

Pertains to the expenses relating to our long-term incentive plan (the "LTIP"), along with associated payroll taxes.

 
 

(2)

 
  

Expenses for legal, due diligence, regulatory, tax, and fairness opinions relating to the Nutrawise acquisition.

 
 

(3)

 
  

Relates to system implementation costs to advance our supply chain planning infrastructure. Unlike other system improvement projects with costs capitalized, due to its cloud-based nature, these system implementation costs are expensed accordingly.

 
 

(4)

 
  

Costs related to COVID-19 which do not reflect the ongoing costs of operation.

 
 

(5)

 
  

Prior year expenses mainly pertained to start-up costs to complete our transition to a third-party logistics provider to make room for capacity expansion at our existing operations.

 
 

(6)

 
  

Costs pertaining to our LTIP, excluding certain one-time grants to certain employees. Prior year expenses included the acceleration of share-based compensation expense in relation to our CEO transition, net of tax benefits realized on the vesting of certain share-based awards.

 
 

 

 

  

  

  Investor and Media Contact Information:  
Jamieson Wellness
Ruth Winker
416-705-5437
rwinker@jamiesonlabs.com  

 

News Provided by Business Wire via QuoteMedia

JWEL:CA
The Conversation (0)
Various blister packs with pills and capsules in different colors and shapes.

Trump Signs Sweeping Order to Slash Drug Prices, Pressure Pharma Giants

US President Donald Trump has signed a sweeping executive order aimed at dramatically reducing prices for prescription drugs, vowing to end “foreign free-riding” on American pharmaceutical innovation.

The order directs federal agencies to pressure both drug manufacturers and wealthy foreign countries to bring their prices in line with those paid in the US, or face aggressive trade and regulatory actions.

“In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism abroad with skyrocketing prices at home,” Trump states in the order.

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2025

The global pharmaceutical market reached a total value of US$1.38 trillion in 2024, according to Research and Markets, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Invion Limited

Invion Limited

Keep reading...Show less
Large pharmaceutical pill with gold dollar sign in the middle. Stock tickers and charts in the background.

Top 5 Small-cap Pharma Stocks in 2025

Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval.

However, the industry's major underlying drivers — higher rates of cancer and chronic disease — are still at play and not expected to dissipate.

The US reigns supreme in the pharma market, both in terms of drug demand and development. In 2024, 50 novel medicines were approved by the US Food and Drug Administration (FDA), compared to 55 such approvals in 2023. Last year's FDA approvals include Eli Lilly and Company's (NYSE:LLY) Alzheimer's disease treatment Kisunla.

Big pharma largely steals the show, but some small- and mid-cap NASDAQ pharma stocks have also made gains.

Keep reading...Show less
Cardiol Therapeutics (TSX:CRDL)

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trial

Completed patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patients
with acute myocarditis, with topline data expected in Q2 2025

Keep reading...Show less

Latest Press Releases

Related News

×